Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

被引：0
|
作者：
Van Cutsem, E. [1 ,2 ]
Amonkar, M. [3 ]
Fuchs, C. S. [4 ]
Alsina, M. [5 ,6 ]
Ozguroglu, M. [7 ]
Bang, Y-J. [8 ]
Chung, H. C. [9 ]
Muro, K. [10 ]
Goekkurt, E. [11 ]
Benson, A. [12 ]
Sun, W. [13 ]
Wainberg, Z. A. [14 ]
Norquist, J. [3 ]
Chen, X. [3 ]
Shih, C-S. [3 ]
Shitara, K. [15 ]
机构：
[1] Univ Hosp Gasthuisberg Leuven, Digest Oncol, Leuven, Belgium
[2] Katholieke Univ Leuven, Leuven, Belgium
[3] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[4] Yale Canc Ctr, Med Oncol, New Haven, CT USA
[5] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[6] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain
[7] Istanbul Univ Cerrahpasa, Clin Trial Unit, Cerrahpasa Sch Med, Internal Med,Med Oncol, Istanbul, Turkey
[8] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea
[9] Yonsei Univ, Med Oncol, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[10] Aichi Canc Ctr Hosp, Clin Oncol, Nagoya, Aichi, Japan
[11] Univ Canc Ctr Hamburg, HOPE, North German Trial Ctr Innovat Oncol NIO, Hamburg, Germany
[12] Northwestern Med Fac Fdn, Hematol Oncol, Chicago, IL USA
[13] Univ Kansas, Internal Med, Med Oncol, Westwood, KS USA
[14] Univ Calif Los Angeles, David Geffen Sch Med, Med Hematol & Oncol, Los Angeles, CA 90095 USA
[15] Natl Canc Ctr Hosp, Gastrointestinal Oncol, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
791P
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [11] Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
    Mansoor, Wasat
    Kulkarni, Amit S.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Sunpaweravong, Patrapim
    Alsina, Maria
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Norquist, Josephine
    Shah, Sukrut
    Shen Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [12] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [13] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
    Tabernero, J.
    Van Cussem, E.
    Bang, Y.
    Fuchs, C.
    Wyrwicz, L.
    Lee, K.
    Kudaba, I.
    Garrido, M.
    Chung, C.
    Salguero, C. Castro
    Mansoor, W.
    Braghiroli, M.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z.
    Kher, U.
    Shah, S.
    Karg, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
  • [14] Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).
    Adenis, Antoine
    Kulkarni, Amit
    Girotto, Gustavo Colagiovanni
    De La Fouchardiere, Christelle
    Senellart, Helene
    Van Laarhoven, Hanneke W. M.
    Hochhauser, Daniel
    Mansoor, Wasat
    Al-Rajabi, Raed
    Norquist, Josephine
    Suryawanshi, Shailaja
    Bhagia, Pooja
    MetgesInstitut, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [15] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
  • [16] Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.
    De Wit, Ronald
    Bajorin, Dean F.
    Bellmunt, Joaquim
    Fradet, Yves
    Lee, Jae-Lyun
    Fong, Lawrence
    Vogelzang, Nicholas J.
    Climent, Miguel Angel
    Petrylak, Daniel Peter
    Choueiri, Toni K.
    Necchi, Andrea
    Gerritsen, Winald R.
    Gurney, Howard
    Quinn, David I.
    Culine, Stephane
    Sternberg, Cora N.
    Mai, Yabing
    Li, Haojie
    Perini, Rodolfo F.
    Vaughn, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [17] Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results
    Janjigian, Yelena Y.
    Kawazoe, Akihito
    Xu, Jianming
    Lonardi, Sara
    Metges, Jean-Philippe
    Wyrwicz, Lucjan S.
    Shen, Lin
    Ostapenko, Yuriy
    Bilici, Mehmet
    Lowery, Maeve Aine
    Valderrama, Adriana
    Guan, Yanfen
    Li, Kan
    Shih, Chie-Schin
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 286 - 286
  • [18] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
    Adenis, Antoine
    Kulkarni, Amit S.
    Girotto, Gustavo C.
    de la Fouchardiere, Christelle
    Senellart, Helene
    van Laarhoven, Hanneke W. M.
    Mansoor, Wasat
    Al-Rajabi, Raed
    Norquist, Josephine
    Amonkar, Mayur
    Suryawanshi, Shailaja
    Bhagia, Pooja
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04) : 382 - +
  • [20] Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
    Kim, H. R.
    Awad, M. M.
    Navarro, A.
    Gottfried, M.
    Peters, S.
    Csoszi, T.
    Cheema, P. K.
    Rodriguez-Abreu, D.
    Wollner, M.
    Yang, J. C-H.
    Mazieres, J.
    Orlandi, F. J.
    Luft, A.
    Gumus, M.
    Kato, T.
    Kalemkerian, G. P.
    Luo, Y.
    Santorelli, M. L.
    Pietanza, M. C.
    Rudin, C. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1033 - S1034
12345